Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease

Use of a new monoclonal antibody-based assay

Olaf Schulz, Markus Reinicke, Jochen Krämer, Gunnar Berghöfer, Ricarda Bensch, Ingolf Schimke, Allan S Jaffe

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: PAPP-A is promising in improving risk stratification and invasive treatment decisions in stable cardiovascular patients. We evaluated the prognostic value of pregnancy-associated plasma protein A (PAPP-A) measured by a novel assay in stable cardiovascular patients. Methods: We investigated 228 stable cardiovascular outpatients. Blood was drawn for PAPP-A measurement after echocardiography and ergometry prior to heart catheterization. Angiographically we determined severity as well as qualitative characteristics suspect for vulnerability of coronary lesions. After 1108 ± 297. days, follow-up information was obtained by questionnaire mailings and interviews by phone. Results: 104 patients had coronary stenosis ≥ 70%, 75 had B-type lesions ≥ 50%, 46 showed complex lesions, and 68 were suspected to have vulnerable lesions. Median PAPP-A was 1.76 (interquartile range 1.21, 2.63) μIU/ml in the entire cohort. PAPP-A concentrations did not differ in dependence on coronary artery findings. A cutpoint of 2.7. μIU/ml was derived from receiver-operator characteristics for outcome measures. For this cutoff, Cox proportional hazard models with 19 further clinical variables showed that PAPP-A was predictive for all-cause death (HR 4.73, 95% CI 1.46-15.31, p = 0.01), all-cause death or nonfatal infarction (HR 4.01, 95% CI 1.58-10.13, p = 0.003) and all-cause death, nonfatal myocardial infarction or hospitalization (HR 1.96, 95% CI 1.03-3.70, p = 0.04). The predictive value of PAPP-A did not change substantially after correction for values of cardiac troponin, using a highly sensitive cardiac troponin I research assay. Conclusions: PAPP-A, measured by a new, monoclonal antibody-based assay is a promising prognostic marker in patients with stable cardiovascular disease and an indication for heart catheterization.

Original languageEnglish (US)
Pages (from-to)880-886
Number of pages7
JournalClinica Chimica Acta
Volume412
Issue number11-12
DOIs
StatePublished - May 12 2011

Fingerprint

Pregnancy-Associated Plasma Protein-A
Assays
Cardiovascular Diseases
Monoclonal Antibodies
Cause of Death
Cardiac Catheterization
Echocardiography
Ergometry
Troponin
Troponin I
Coronary Stenosis
Proportional Hazards Models
Infarction
Coronary Vessels
Hazards
Hospitalization
Blood
Outpatients
Myocardial Infarction
Outcome Assessment (Health Care)

Keywords

  • PAPP-A
  • Prognosis
  • Stable cardiovascular disease

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease : Use of a new monoclonal antibody-based assay. / Schulz, Olaf; Reinicke, Markus; Krämer, Jochen; Berghöfer, Gunnar; Bensch, Ricarda; Schimke, Ingolf; Jaffe, Allan S.

In: Clinica Chimica Acta, Vol. 412, No. 11-12, 12.05.2011, p. 880-886.

Research output: Contribution to journalArticle

Schulz, Olaf ; Reinicke, Markus ; Krämer, Jochen ; Berghöfer, Gunnar ; Bensch, Ricarda ; Schimke, Ingolf ; Jaffe, Allan S. / Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease : Use of a new monoclonal antibody-based assay. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 11-12. pp. 880-886.
@article{2c801219243a40a6b1c6c9ada3c6bb00,
title = "Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay",
abstract = "Background: PAPP-A is promising in improving risk stratification and invasive treatment decisions in stable cardiovascular patients. We evaluated the prognostic value of pregnancy-associated plasma protein A (PAPP-A) measured by a novel assay in stable cardiovascular patients. Methods: We investigated 228 stable cardiovascular outpatients. Blood was drawn for PAPP-A measurement after echocardiography and ergometry prior to heart catheterization. Angiographically we determined severity as well as qualitative characteristics suspect for vulnerability of coronary lesions. After 1108 ± 297. days, follow-up information was obtained by questionnaire mailings and interviews by phone. Results: 104 patients had coronary stenosis ≥ 70{\%}, 75 had B-type lesions ≥ 50{\%}, 46 showed complex lesions, and 68 were suspected to have vulnerable lesions. Median PAPP-A was 1.76 (interquartile range 1.21, 2.63) μIU/ml in the entire cohort. PAPP-A concentrations did not differ in dependence on coronary artery findings. A cutpoint of 2.7. μIU/ml was derived from receiver-operator characteristics for outcome measures. For this cutoff, Cox proportional hazard models with 19 further clinical variables showed that PAPP-A was predictive for all-cause death (HR 4.73, 95{\%} CI 1.46-15.31, p = 0.01), all-cause death or nonfatal infarction (HR 4.01, 95{\%} CI 1.58-10.13, p = 0.003) and all-cause death, nonfatal myocardial infarction or hospitalization (HR 1.96, 95{\%} CI 1.03-3.70, p = 0.04). The predictive value of PAPP-A did not change substantially after correction for values of cardiac troponin, using a highly sensitive cardiac troponin I research assay. Conclusions: PAPP-A, measured by a new, monoclonal antibody-based assay is a promising prognostic marker in patients with stable cardiovascular disease and an indication for heart catheterization.",
keywords = "PAPP-A, Prognosis, Stable cardiovascular disease",
author = "Olaf Schulz and Markus Reinicke and Jochen Kr{\"a}mer and Gunnar Bergh{\"o}fer and Ricarda Bensch and Ingolf Schimke and Jaffe, {Allan S}",
year = "2011",
month = "5",
day = "12",
doi = "10.1016/j.cca.2011.01.009",
language = "English (US)",
volume = "412",
pages = "880--886",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "11-12",

}

TY - JOUR

T1 - Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease

T2 - Use of a new monoclonal antibody-based assay

AU - Schulz, Olaf

AU - Reinicke, Markus

AU - Krämer, Jochen

AU - Berghöfer, Gunnar

AU - Bensch, Ricarda

AU - Schimke, Ingolf

AU - Jaffe, Allan S

PY - 2011/5/12

Y1 - 2011/5/12

N2 - Background: PAPP-A is promising in improving risk stratification and invasive treatment decisions in stable cardiovascular patients. We evaluated the prognostic value of pregnancy-associated plasma protein A (PAPP-A) measured by a novel assay in stable cardiovascular patients. Methods: We investigated 228 stable cardiovascular outpatients. Blood was drawn for PAPP-A measurement after echocardiography and ergometry prior to heart catheterization. Angiographically we determined severity as well as qualitative characteristics suspect for vulnerability of coronary lesions. After 1108 ± 297. days, follow-up information was obtained by questionnaire mailings and interviews by phone. Results: 104 patients had coronary stenosis ≥ 70%, 75 had B-type lesions ≥ 50%, 46 showed complex lesions, and 68 were suspected to have vulnerable lesions. Median PAPP-A was 1.76 (interquartile range 1.21, 2.63) μIU/ml in the entire cohort. PAPP-A concentrations did not differ in dependence on coronary artery findings. A cutpoint of 2.7. μIU/ml was derived from receiver-operator characteristics for outcome measures. For this cutoff, Cox proportional hazard models with 19 further clinical variables showed that PAPP-A was predictive for all-cause death (HR 4.73, 95% CI 1.46-15.31, p = 0.01), all-cause death or nonfatal infarction (HR 4.01, 95% CI 1.58-10.13, p = 0.003) and all-cause death, nonfatal myocardial infarction or hospitalization (HR 1.96, 95% CI 1.03-3.70, p = 0.04). The predictive value of PAPP-A did not change substantially after correction for values of cardiac troponin, using a highly sensitive cardiac troponin I research assay. Conclusions: PAPP-A, measured by a new, monoclonal antibody-based assay is a promising prognostic marker in patients with stable cardiovascular disease and an indication for heart catheterization.

AB - Background: PAPP-A is promising in improving risk stratification and invasive treatment decisions in stable cardiovascular patients. We evaluated the prognostic value of pregnancy-associated plasma protein A (PAPP-A) measured by a novel assay in stable cardiovascular patients. Methods: We investigated 228 stable cardiovascular outpatients. Blood was drawn for PAPP-A measurement after echocardiography and ergometry prior to heart catheterization. Angiographically we determined severity as well as qualitative characteristics suspect for vulnerability of coronary lesions. After 1108 ± 297. days, follow-up information was obtained by questionnaire mailings and interviews by phone. Results: 104 patients had coronary stenosis ≥ 70%, 75 had B-type lesions ≥ 50%, 46 showed complex lesions, and 68 were suspected to have vulnerable lesions. Median PAPP-A was 1.76 (interquartile range 1.21, 2.63) μIU/ml in the entire cohort. PAPP-A concentrations did not differ in dependence on coronary artery findings. A cutpoint of 2.7. μIU/ml was derived from receiver-operator characteristics for outcome measures. For this cutoff, Cox proportional hazard models with 19 further clinical variables showed that PAPP-A was predictive for all-cause death (HR 4.73, 95% CI 1.46-15.31, p = 0.01), all-cause death or nonfatal infarction (HR 4.01, 95% CI 1.58-10.13, p = 0.003) and all-cause death, nonfatal myocardial infarction or hospitalization (HR 1.96, 95% CI 1.03-3.70, p = 0.04). The predictive value of PAPP-A did not change substantially after correction for values of cardiac troponin, using a highly sensitive cardiac troponin I research assay. Conclusions: PAPP-A, measured by a new, monoclonal antibody-based assay is a promising prognostic marker in patients with stable cardiovascular disease and an indication for heart catheterization.

KW - PAPP-A

KW - Prognosis

KW - Stable cardiovascular disease

UR - http://www.scopus.com/inward/record.url?scp=79954989606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954989606&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2011.01.009

DO - 10.1016/j.cca.2011.01.009

M3 - Article

VL - 412

SP - 880

EP - 886

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 11-12

ER -